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ABSTRACT 
 
Background: Intrauterine devices (IUD) are an increasingly popular form of contraception in the 
US due to their high level of effectiveness, reversibility, and lack of further maintenance after 
insertion, but they are not without their adverse events. Previous studies have found that local 
adverse events following IUD insertion can be problematic enough that women choose to remove 
them. While much research has been done on IUDs and their related adverse events, in outpatient 
settings, no research has been done regarding comorbid conditions associated with their removal 
in an inpatient setting. Comorbidities associated with IUD removal may point to systemic long-
term effects of IUD use that can be further explored. The primary objective of this study is to 
describe and examine the association of patient factors and comorbid conditions with inpatient 
IUD placement and removal compared to the inpatient controls. 
Methods: An analysis of data from the US National Inpatient Sample from 2010-2014 was 
performed looking for an association between various potential comorbidities (vascular, 
allergy/immune, and endometriosis) when the hospitalization includes an IUD insertion or no IUD 
procedure, compared to an IUD removal. The inpatient samples were matched using propensity 
score of having an IUD related ICD-9 code to create triplets of women with no IUD procedure, 
IUD insertion, and IUD removal.  
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Results: IUD removal is associated with a decreased likelihood of hypertension, cardiovascular 
disease and peripheral vascular disease, and an increased likelihood of endometriosis compared to 
women without an IUD procedure indicating they may be adverse events of using an IUD leading 
to an IUD removed. There were no significant statistical interactions found between race and IUD 
group, though some trends between races were seen. 
Conclusion: As more women in the United States are choosing IUDs as their preferred 
contraceptive method, we have identified associated comorbid conditions among IUD users 
though we did not have strong evidence to support that these effects vary by race. This will have 
a public health impact by informing future research on the potential long-term systemic adverse 
events to allow women and their doctors to make their most informed decision about contraceptive 
use.  
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1.0  INTRODUCTION 
 FAMILY PLANNING METHODS 
In 2016, approximately 43 million of the 61 million women (70%) in the United States of child 
bearing age were at risk of an unplanned pregnancy. In order to prevent becoming pregnant while 
remaining sexually active, either the woman and/or her partner needs to engage in family planning 
methods. The typical American woman needs to use family planning methods for around 30 years1. 
There are many benefits to family planning. The ability to plan when a woman becomes 
pregnant allows her to better time and space births as well as meet her educational and workforce 
goals which have positive impacts on income, family stability, mental health and happiness, and 
children’s well-being while also allowing for healthier pregnancies. 
 Though contraception use has many benefits, there are risks associated with it, particularly 
in contraceptive methods involving hormones. These risks include coronary heart disease, 
hypertension, stroke, venous thromboembolic disease, risk of breast cancer, change in cholesterol, 
liver disorders, and headache among others. 
The contraception types available today fall into six general categories: natural family 
planning, barrier methods, oral contraceptives, emergency contraceptives, injectable progestin,  
long-acting reversible contraceptives (including intrauterine devices (IUD)), and sterilization2. 
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Natural family planning involves tracking a woman’s menstrual cycle through basal body 
temperature, cervical mucus, ovulation predictor kits, cycle beads, or the tracking of cycle days. 
The U.S. Department of Health and Human Services estimate that natural family planning is 
around 75% effective2. While this is not the most effective form of contraceptive, it does not 
require a physician’s prescription. 
Barrier methods include diaphragms, contraceptive sponges, cervical caps, female 
condoms, and spermicide for women and latex condoms for men which also help prevent the 
spread of sexually transmitted infections. These methods require personal skill for correct usage 
as well as continued use during each sexual intercourse encounter for effectiveness. In addition, 
diaphragm and cervical caps require a doctor’s prescription to ensure the correct size, though other 
barrier methods can be used without the need for a physician. These methods have no major 
contraindications. The effectiveness varies by correct usage and method but ranges from 
approximately 75-90%2. Some couples use barrier methods along with the natural family planning 
method to increase the efficacy2. 
Oral contraceptives contain estrogen and progesterone or progesterone alone to prevent 
pregnancy2. Additionally, oral contraceptives are used to treat other clinical symptoms such as 
abnormal uterine bleeding, hyperandrogenism, dysmenorrhea, ovarian suppression, excess 
menstrual bleeding, menstrual pain, endometriosis, and acne1-3. Oral contraceptives have many 
contraindications and potential adverse events so they require a physician’s prescription before 
initiating use to ensure an appropriate oral contraceptive is selected. Contraindications for use 
depend on the type of oral contraceptive and include cancer, cardiovascular diseases, migraines, 
hypertension, thromboembolic events, body mass index, smoking, and age, among others. Some 
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adverse events include breakthrough bleeding, amenorrhea, weight gain, and increased blood 
pressure. Oral contraceptives are approximately 91% effective2.  
Emergency contraception was developed to prevent fertilization after intercourse had 
already occurred and generally involves a high-dose administration of estrogen as soon as possible 
after intercourse, some without the need of a physician prescription. Emergency contraception has 
a higher risk for adverse events2. It is estimated that emergency contraception reduces the 
incidence of pregnancy by 90% when used after one unprotected sex event1. 
Depot formulations of progestin may be injected intramuscularly or subcutaneously by a 
physician every 13 weeks. It should not be used by women who may wish to become pregnant 
quickly after termination of use as fertility is not instantly regained upon discontinuation. 
Injectable progestin is 94% effective and can also be used for dysmenorrhea and amenorrhea2. 
Long-acting reversible contraception (LARC), including intrauterine devices and 
progesterone implants, provide contraception for a period of years after placement and are over 
99% effective. Insertion in a physician’s office is required to ensure proper placement. By 
definition, LARCs must be able to remain inserted for at least three years and are considered 
“forgettable” due to the lack of routine maintenance or further patient action after insertion. Due 
to their effectiveness, reversibility, and lack of further patient action, they are highly recommended 
by gynecologists2. 
Permanent sterilization includes tubal ligation for females and vasectomies for males. 
Effectiveness for permanent sterilization is similar to those of LARCs: 99.5% for tubal ligation 
and 99.85% for vasectomies. Vasectomy is an outpatient procedure while tubal ligation is often an 
inpatient procedure. Some hysteroscopic sterilization procedures, such as Essure, can be 
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performed in a doctor’s office. Vasectomies are the safest and most cost effective sterilization 
procedure while tubal ligation can have adverse events including ectopic pregnancies2. 
 INTRAUTERINE DEVICES (IUD) 
1.2.1 What is an IUD? 
An increasingly popular form of contraception is the intrauterine device (IUD) because it is long 
lasting as well as reversible; 3,884,000 American women used IUDs in 2011 1,3-9.  An IUD is a 
small, t-shaped device that a healthcare provider inserts in the uterus and is held in place by the 
cervix10. The insertion and removal of an IUD usually occurs in an outpatient setting in the doctor’s 
office. Once an IUD is inserted, it provides contraceptive benefits for up to ten years. There are 
two main types of IUDs in the US: copper and hormonal (Figures 1 and 2)7,10,11. Copper IUDs 
work by releasing copper ions that prevent sperm from reaching and therefore fertilizing the egg. 
These copper ions affect the mobility and viability of the sperm. In the rare case where the egg is 
fertilized, the inflammation caused by the copper IUD prevents the egg from implanting on the 
endometrium and, thereby, allows the copper IUD to be inserted up to five days after ovulation 
and still provide contraceptive benefit. As a result, copper IUDs are the most effective form of 
emergency contraception with nearly a 100% effectiveness rate 2,3,7,12,13.  Hormonal IUDs contain 
a progestin which causes cervical mucus to thicken and the uterine lining to thin which prevents 
the sperm from reaching the egg10. 
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Both types of IUDs are approved with few contraindications. The common 
contraindications include known or suspected pregnancy,  active pelvic infection (e.g. immediately 
after a septic abortion), and distortions of endometrial cavity (e.g. fibroids)2. IUDs are approved 
for immediate use after abortions and after giving birth (both vaginal and cesarean delivery), 
including while a woman is breast feeding.3,7 They are also approved for use in adolescents and 
HIV-positive women, two groups that have difficulty accessing other forms of contraception such 
as oral pills3. In addition to contraceptive benefits, both hormonal and copper IUDs can be used to 
treat menorrhagia and endometrial hyperplasia.  
IUDs are currently among the most effective form of birth control with less than 1 in 100 
women getting pregnant while using an IUD (2 per 1000 in hormonal IUD and 8 per 1000 in 
copper IUDs) 2,3,10. Because IUDs require no maintenance, it is the only form of contraception that 
has nearly perfect usage, allowing for the maximum contraceptive effect1,3,4,9. If a woman removes 
an IUD and uses a different form of contraception, she will always be switching to a less effective 
form of contraception (except for permanent sterilization or another LARC such as a progesterone 
Figure 1. Picture of copper IUD. Figure 2. Picture of hormonal IUD. 
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implant), so doctors discourage women from having their IUDs removed unless they have decided 
that they want to become pregnant. 
1.2.2 Trends in use 
According to a study that analyzed trends in IUD use in America using data from the National 
Surveys of Family Growth (NSFG), IUD use increased from 1.8% to 9.5% from 2002 and 2011-
201314. The increase in IUD use appears to largely have come from users of the oral contraceptive 
pill which have dropped from 26.4% to 22.0% from 2002 to 2012, while the rate of women not 
using contraception of any kind have remained the same (10.9% in 2002 and 10.2% in 2012). The 
increase in IUD use is concentrated in women aged 25-34 years. IUD usage increased in all ethnic 
groups with foreign-born Hispanic women having the highest rates of use (16.9%). According to 
the Reproductive Health Report, 2011, the increase in use from 2002-2012 was higher in women 
who wanted more children versus those that didn’t (15.1% and 7.7% respectively)14.  This implies 
that women use IUDs more frequently to help space out births compared to wanting to not have 
any more children or not having giving birth yet. IUDs have been found to have the highest rates 
of continuation and satisfaction compared to other forms of birth control (over 80%)15,16. 
 While much literature supports the use of IUDs, there are widespread misconceptions about 
IUDs that present a barrier to women choosing to use IUDs. A review article on perceptions on 
IUD use found that only 20% of women in the primary care setting knew that IUDs are more 
effective than oral contraception with male knowledge of IUD effectiveness also being very poor3. 
In one study, almost half of the participants surveyed thought that IUDs were banned in the US3. 
The position in the body was also found to be a concern for many patients globally with a study in 
Scotland showing 24% of women fearing that the device could move in the body3. Global concerns 
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about IUD insertion or IUD removal showed that women were worried about pain and 
infringement on modesty. Two studies found that having an option for the patient to remove the 
IUD themselves would encourage them to choose an IUD3. 
IUD acceptability is not only a function of personal knowledge, but also of acceptability 
within a person’s social group. A study by Gomez and Freihart found that interest in an IUD was 
influenced by experiences of people they know17. They found that even if women had heard 
positive things about IUDs, at least one person who had a peer with a negative experience caused 
them to no longer be interested in having an IUD inserted17. Women whose providers used IUDs 
themselves increased the likelihood of the woman choosing an IUD for herself, though qualitative 
studies in low-income settings found that reassurance from friends and families was a much more 
crucial factor to encourage IUD use with negative conversations having a more lasting impact than 
positive ones3,18. Women said that they don’t necessarily discuss contraception when it works but 
rather only when there are concerns or problems. Women find these conversations to be 
memorable18.  Patients were wary to use methods even if they were recommended by their doctor 
after hearing negative adverse events from people in their social circle18. Nearly 80% of users in 
the Anderson et al. study recommended the use of IUDs to their friends18. Positive perceptions 
received from social circles and patients include high effectiveness, long-lasting effect, and the 
potential for beneficially perceived adverse events such as amenorrhea18. Among women who are 
well informed about IUDs, high effectiveness, the quick return of fertility upon removal, the ability 
to use while breastfeeding, the potential for amenorrhea, and the lack of daily maintenance were 
cited as reasons for use of IUDs over other forms of contraception3,18. 
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1.2.3 Factors influencing decision to remove IUD 
IUDs are an excellent form of contraception, but when individuals discontinue their IUD, they 
often revert back to a contraception method of lesser efficacy. IUDs are usually well tolerated in 
patients with only 10-20% of women discontinuing use within the first year19,20. Two major factors 
that have been shown to impact a woman’s decision to stop using an IUD are: 1) the symptoms 
and adverse events that they experience and 2) the perceptions of the patient which are largely 
influenced by their social circle. 
1.2.3.1 IUD-related adverse events 
While IUDs are considered by gynecologists to be a very effective and safe form of contraception, 
there are adverse events attributed to IUD use. The primary reason a woman requests an early IUD 
removal is due to these adverse events19,20. As an example, inflammation due to the insertion of a 
copper IUD leads to a 30% or more increase in menstrual flow which may or may not decrease 
with time and is the largest reason for discontinued use in copper IUDs21,22.  
Tables 1-3 present adverse events associated with IUD use and the studies that reported 
them. Table 1 presents the short term adverse event that can happen at the time of IUD insertion 
which consists of perforation of the uterus. This is a serious issue that requires surgery.  
 
 
Table 1. Short term adverse events associated with IUD use as seen in the literature. 
 
Short Term Adverse Event Support 
Perforation of the Uterine Wall Howard et al5, Bateson et al21, Aoun et al16 
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Table 2 presents adverse events that can occur at any point while using an IUD with the 
most common being bleeding and pain. These adverse events include some of the most common 
issues that women report when they request to have an IUD removed. 
 
 
Table 2. Short or long term adverse events with IUD use as seen in the literature. 
 
 
Table 3 presents long term adverse events of IUD use which include local and systemic 
effects. Some of these systemic effects include increased blood pressure and dermatitis/eczema. It 
is well accepted that IUDs act locally so adverse events such as vaginal infections are expected. 
Women have also reported systemic adverse events such as weight gain which have mixed 
evidence in the literature and may be due to confounding7. This study attempts to look at both local 
and systemic adverse events that may be related to IUD use. 
 
Short or Long Term Adverse Event Support 
Menorrhagia Nelson et al
4, Howard et al5, Bateson et al21, 
Bahamondes et al8 
Menstrual Bleeding Irregularities Nelson et al
4, Dickerson et al9, Bahamondes et al8, 
Amico et al (2016)19, Amico et al (2017)19 
Dysmenorrhea Nelson et al4, Howard et al5, Bateson et al21 
Pelvic Inflammatory Disease Howard et al5, Aoun et al16 
Pelvic Pain Howard et al5, Bateson et al21, Bahamondes et al8 
Intermenstrual Bleeding Bateson et al21 
Dyspareunia Bateson et al21 
Malposition Bateson et al21 
Expulsion Bateson et al21 
Failures Bateson et al21 
Ectopic Pregnancy Bateson et al21, Aoun et al16 
Increased Frequency of Menstrual Bleeding Dickerson et al9 
Lower Abdominal Pain Bahamondes et al8 
Prolonged Bleeding Bahamondes et al8 
Cramping Amico et al (2016)19, Amico et al (2017)20 
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Table 3. Long term adverse events with IUD use as seen in the literature. 
 
1.2.3.2 Perceptions of the patient and their social circle 
Women’s decisions regarding IUD removal are also influenced by the experiences and perceptions 
had by people in their social circles as introduced in section 1.2.2. Anderson et al. found that the 
major negative topic around IUDs women talk about are the adverse events such as perforation, 
migration, heavy bleeding, cramping, failure, problems with return of fertility, and death18. While 
some women admitted that they knew these stories may not be true, it was enough to scare them 
into having their IUD removed. The source of negative stories from family and friends most 
frequently came from television commercials as well as personal stories from family and friends18.  
 Amico et al. (2016) found that potential or suspected adverse events were a contributing 
factor for the interest in removing the IUD such as concern for internal damage, that the IUD was 
not correctly placed, or that it was causing an infection19. Amico et al. also found that while patients 
Long term adverse event Support 
Weight Gain Nelson et al4, Dickerson et al9, Peipert et al15 
Loss of Sexual Desire/Changes in Libido Nelson et al4 
Mood Changes Nelson et al4 
Amenorrhea Nelson et al4, Howard et al5, Dickerson et al9 
Breast Tenderness/Enlargement Nelson et al4 
Water Retention/Bloating Nelson et al4, Amico et al (2016)19 
Headaches/Migraines Nelson et al4, Dickerson et al9, Bahamondes et al8 
Fatigue Nelson et al4 
Increase in Vaginal Discharge Nelson et al4, Bateson et al21, Amico et al (2016)19 
Concern About Not Being Able to Get Pregnant After Stopping Nelson et al4 
Nausea/Vomiting Nelson et al4 
Vaginal Dryness Nelson et al4 
Blood Clots/Risk of Stroke Nelson et al4 
Yeast Infection/Vaginal Iinfection Nelson et al4, Howard et al5, Amico et al (2016)19 
Dizziness Nelson et al4, Bahamondes et al8 
Hair Loss Nelson et al4, Dickerson et al9 
Increased Blood Pressure Nelson et al4 
Anemia Howard et al5 
Ovarian Cysts Howard et al5 
Acne Bahamondes et al8, Peipert et al15 
Dermatitis/Eczema Fage, Faurshou, & Thyssen23 
Depression Dickerson et al9 
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were warned about the potential for bleeding or cramping, the women who were considering the 
removal of IUDs had symptoms that were more severe or of longer duration than they expected or 
that they had additional adverse events such as vaginal discharge, bloating, yeast infections, and 
other urinary tract infections19. 
1.2.4 Removal of IUDs 
When women request that their IUD be removed, doctors often advise they wait to determine if 
the adverse events resolve themselves19. This is especially true if the patient has had the IUD 
inserted for less than a year. This is frustrating to the patients because most of them have already 
waited what they consider a significant amount of time before consulting a doctor about getting 
their IUD removed19.  
Amico et al. (2016) found that many women who wanted to have their IUD removed felt 
that their doctor’s expressed disinterest in removing the IUD discouraged them from having the 
IUD removed19. The required office visit along with perceived coercion into women not removing 
IUDs from their doctors can lead to perceived lack of autonomy in reproductive choice so some 
women choose to try to remove the IUD themselves19,20,22. While IUDs were designed to be 
removed by a healthcare professional, there is nothing dangerous about a woman removing an IUD 
herself. Foster et al. found that only 20% of these women were successful in removing their own 
IUD. The odds of success increased with each additional centimeter in length of the strings coming 
off the IUD and if the woman had previously felt the strings22. 
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 IUD USE IN THE INPATIENT SETTING 
The insertion and removal of an IUD is usually performed within an outpatient setting in a doctor’s 
office, not in the hospital. Insertion of an IUD in the hospital occurs as a concurrent procedure 
during another surgical procedure (e.g. placement of IUD after treating ovarian cysts or abnormal 
uterine bleeding) or is placed after recent pregnancy. Removal of an IUD is related to the treatment 
of another medical condition present during the inpatient hospitalization. Providers in the hospital 
would not generally address requests for the removal of an IUD when it is unrelated to the reason 
for hospitalization. 
In most cases, a woman entering the hospital would not need to have her IUD removed.  
Women may have an IUD removed in the hospital if the symptoms are localized to the reproductive 
system such as pelvic pain or infection to rule out the IUD as related to the symptoms. For example, 
if a woman presented with persistent pelvic inflammatory disease even after antibiotic use, doctors 
may remove her IUD to see if that alleviates her symptoms and helps eliminate the infection. In 
general, an IUD should only be removed after careful discussion with her established women’s 
health provider. When a woman’s IUD is removed, she should use an alternate form of 
contraception and be informed that she is at an increased risk for pregnancy as other common types 
of contraception are less effective than an IUD. There is a gap in knowledge about why women 
have an IUD removed in a hospital, especially in regards to specific conditions that influenced her 
decision to have an IUD removed. In this study, we will focus on the association between comorbid 
medical conditions and IUD removal. 
Little is known about IUD insertion and removal in a hospital setting. All previous research 
has been performed in outpatient settings. Yet, many serious conditions are treated in hospital 
settings, and so IUD insertion or removal in this setting are important to patients and providers. 
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This knowledge could help improve our knowledge of contraceptive services and risk for 
discontinuation of IUDs as well as potential IUD related complications and/or long-term systemic 
effects.  
 MAIN QUESTION/SETTING 
We conducted explorative research on in-hospital comorbidities among IUD users in order to 
identify potential IUD-related adverse health outcomes that have not been fully recognized. Our 
study objectives included: 1) investigate if there is a correlation between putative adverse health 
outcomes and IUD use by comparing their frequencies among in-hospital women subpopulations 
with IUD removal and their counterparts with IUD insertion or no IUD procedure and 2) identify 
if there are racial differences in the prevalence of certain comorbidities among inpatient women 
with IUD removal vs. those with no IUD procedure. We used Data from the National Inpatient 
Sample from the Agency for Healthcare Research and Quality (NIS/AHRQ, 2010-2014) to meet 
our objectives. Our outcomes of interest were defined using International Classification of 
Diseases codes (ICD-9) corresponding to previously identified comorbidities to examine their 
association with patient factors (e.g., age and race) among the following inpatient women 
subpopulations: No IUD procedure, IUD removal, or IUD insertion. As a main result of this 
pharmacoepidemiologic research, we expected to elicit underlying conditions and demographic 
factors (e.g., race) that could precipitate the risk of adverse health outcomes in women using IUDs.  
Based on our previous analysis of the entire spectrum of comorbidities with substantially different 
frequencies among inpatient women subpopulations with IUD removal vs. IUD insertion, we 
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focused this analysis on comorbidities related to vascular disease, allergic conditions, and 
endometriosis. 
Following the secondary study objective, we tried to identify if there are racial differences 
in the prevalence of certain comorbidities among inpatient women with IUD removal vs. those 
with IUD insertion. Potential evidence that factors associated with race may impact the risk for 
adverse events upon IUD use may help individualize the choice of best contraceptive methods for 
women. Future pharmacogenetic research, including in silico analysis of known biomarker 
databases, may help to identify putative biomarkers (e.g., Single Nucleotide Polymorphisms - 
SNPs) for certain IUD-associated conditions, thereby further promoting the individualized risk-
benefit assessment and development of Precision Medicine applications pertaining to IUDs.   
15 
2.0  METHOD 
 STUDY POPULATION 
2.1.1 Dataset 
We performed an analysis on NIS data from 2010-2014 looking at IUD insertion and removal 
compared to women without an IUD procedure to examine potential comorbidities associated with 
IUD use. NIS data are sampled from the state inpatient databases as a 20% stratified sample of all 
discharges within United States hospitals (from participating states), excluding rehabilitation and 
long-term acute care hospitals. When the NIS started in 1988, only 8 states participated. With 
participation of 46 states plus Washington DC by 2014, recent NIS data cover 97% of the U.S. 
population and therefore are representative of national trends. The states not included are Alabama, 
New Hampshire, Delaware, and Idaho. The large sample sizes provided by the NIS allow for 
analysis of “rare conditions, uncommon treatments, and special patient populations”24.  
Addressing the need for filling the gap in the literature about the underlying conditions 
pertaining to IUD insertion and removal within the inpatient setting, the NIS dataset was used as 
a representative sample of hospitalizations within the US which contains information related to 
both the exposure (IUD use) and outcomes of interest (adverse health outcomes potentially 
attributable to IUDs). It is important to note, however, that this study is limited to the inpatient 
population and therefore is not representative of the vast majority of IUD insertions and removals 
that are conventionally performed in an outpatient setting. 
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2.1.2 Eligibility criteria 
Inpatient entries from the NIS dataset for the years 2010-2014 were included if the person was 
female of reproductive age which we defined as 15-65 years. In order to be included in the 
propensity matching, the entry had to have complete information for all variables of interest (age, 
race, child delivery, year of inpatient visit, length of stay, quarter of year of discharge, and hospital 
classification). Any entries that had incomplete information were excluded from the matched 
sample. 
2.1.3 Definition of variables 
Cases were classified as having an IUD-related ICD-9 code within the 30 diagnosis codes allotted 
for each inpatient. Entries were classified as having an IUD insertion if their data contained the 
ICD-9 code V25.11, a billing code indicating the insertion of an IUD by a physician. Entries were 
classified as having an IUD removed if the entry contained the ICD-9 code V25.12, a billing code 
indicating the removal of an IUD by a physician. Entries were classified as having an IUD re-
inserted if the entry contained the ICD-9 code V25.13, a billing code indicating the removal and 
re-insertion of an IUD by a physician in the same visit. Women with the re-insertion of an IUD 
were not included in the analysis due to the low frequency. Other entries meeting the eligibility 
criteria that did not have an IUD related billing code were classified as controls not having an IUD 
procedure. 
Baseline characteristics of interest as potential confounders or predictors of IUD status 
were race, age, child delivery code, year of inpatient visit, length of stay, quarter of the year of 
discharge, and hospital classification. Race was classified in two different ways: 1) White, Black, 
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Hispanic, Asian, Native American, and other races and 2) White, Black, and other races. The main 
results are based on race as a three-category variable, but distribution of characteristics was 
analyzed using race in 6 categories. Age was considered both as a continuous variable and as a 
categorical variable with 5 categories: <21 years, 21-30 years, 31-40 years, 41-50 years, and >50 
years. Child delivery code is a binomial variable indicating whether there were maternal codes in 
the inpatient entry. Year of inpatient visit include the years between 2010-2014 when the inpatient 
entry took place. Quarter of the year of discharge was classified as January-March, April-June, 
July-September, and October-December. Hospital classification is a 4-digit variable with each 
digit providing different information about the hospital. This information includes the hospital 
census geography, control (government or private, government nonfederal, private not-for-profit, 
private investor-owned, private neither not-for-profit or investor-owned), urban or rural, teaching 
(rural, urban teaching, urban non-teaching), and bed size (small, medium, large). NIS data prior to 
2012 was classified by census region (Northeast, Midwest, South, West) but from 2012 on the data 
was classified as a more granular census division with two or three divisions corresponding to one 
region. 
Outcomes of interest include potential comorbidities that are classified into vascular 
diseases, allergic/immune conditions, and endometriosis categories. Vascular diseases of interest 
include hypertension, cardiovascular disease, cerebrovascular disease, and peripheral vascular 
disease. Allergic/immune disorders include autoimmune conditions, allergies, rheumatoid 
arthritis, lupus, and a combined variable of dermatitis/eczema/allergic urticaria. Endometriosis was 
classified as endometriosis overall, endometriosis of the uterus, and non-uterine endometriosis. 
The classification codes that were used for each disease are listed in Table 4. 
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Table 4. List of classification codes that defined the diseases of interest. 
Disease Code 
 
Vascular Diseases 
 
Hypertension CCS 98-99 
Cardiovascular Disease CCS 100-108 
Cerebrovascular Disease CCS 109-113 
Peripheral Vascular Disease CCS 114-121 
 
Allergies and Immune Disorders 
 
Autoimmune Disorders CCS 57, 80, 202, 210 
Allergies CCS 128, 198, 253 
Rheumatoid Arthritis CCS 202 
Lupus CCS 210 
Dermatitis/Eczema/Allergic Urticaria ICD-9 692.0-692.3, 693.4, 693.5, 692.6, 692.70, 692.74, 
692.79, 692.81-692.84, 692.89, 692.9, 692.30, 692.31, 
692.38, 693.9, 708.0 
Endometriosis  
Endometriosis CCS 169 (ICD 617.0-617.9) 
Endometriosis of the Uterus (Adenomyosis) ICD 617.0 
Non-Uterine Endometriosis ICD 617.1-617.9 
 
 STATISTICAL METHODS 
2.2.1 Propensity matching 
Due to the rare frequency of inpatient hospitalizations with IUD-related codes, propensity 
matching was performed to create more equally sized groups and make the cases and controls more 
comparable, giving better evidence that any differences found are due to IUD use. Due to the low 
number of women with IUD re-insertions (n=25), they were not included in the analysis. Since the 
IUD group was define as a three-category variable (IUD insertion, IUD removal, and no IUD 
procedure), a two-step propensity score matching process was performed to get matched triplets 
for the analysis. First, a logistic regression was run to determine the probability of having an IUD-
related ICD-9 code based on race, age group, child delivery code, year of inpatient visit, length of 
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stay, quarter of the year of discharge, and the hospital stratum code. Then, women with IUD 
insertion were matched to women with IUD removal based on the propensity of having a diagnosis 
code related to an IUD. The matched women with the removal of an IUD were then matched to 
the control women with no IUD procedure codes. Using this sequence, we expected to create more 
equal groups between the IUD removal and the no IUD procedure group. While the insertions and 
removals were matched, they both were considered as having an IUD-related ICD-9 code and 
therefore, the propensity matching is expected to be less effective in creating comparable IUD 
insertion/IUD removal groups. As a result, we created a matched triplet of patients with an IUD 
insertion, IUD removal, and a no IUD procedure,  giving two controls for each IUD removal case; 
matching was done using PROC PSMATCH in SAS using a greedy 1:1 match with a caliper of 
0.25 standard deviations for each matching step25. 
2.2.2 Preliminary analysis 
Association tests between IUD status group and the baseline characteristics of interest as well as 
between IUD status group and the comorbidities of interest were performed to get pair-wise 
comparison results by IUD status group (No IUD procedure vs. IUD insertion, No IUD procedure 
vs. IUD removal, and IUD insertion vs. IUD removal). In the full, pre-matched sample, categorical 
variables were analyzed using a chi-square test. In the matched sample, categorical variables were 
analyzed with Fisher’s exact test where the expected value was less than 5 or otherwise a chi-
square test for the matched analysis. Continuous variables were analyzed using GLM for both the 
pre-matched and matched samples. ANOVA could not be used because the groups has vastly 
different sample sizes. 
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2.2.3 Matched analysis 
The matched triplets were analyzed using conditional logistic regression for the disease outcomes 
listed in Table 4 conditional on being in the given matched triplet.  
The primary comparison of interest was the IUD removal group to the no IUD procedure 
group and of secondary interest is the IUD removal group compared to the IUD insertion group. 
Three models were used: 1) unadjusted, 2) adjusted for age, year, and child delivery code 3) 
adjusted for covariates from the second model and race. We expect that the added adjustment in 
the second and third models helped reduce the confounding in these variables due to the residual 
differences from the propensity matching of IUD removal and IUD insertion due to their being 
classified in the same propensity score group. The third model was aimed to identify if race may 
affect the relationship between IUD group and the outcome. To better answer this question, an 
analysis of odds ratios of comorbidity based on IUD group stratified by race was analyzed along 
with the interaction between race and IUD group in unadjusted models. If any race category for a 
given outcome was not estimable, the interaction was not tested. The race analysis was performed 
only between the IUD removal and no IUD procedure groups because the models became unstable 
with small sample size and low rates of events in the IUD insertion group. Associations with a p-
value <0.01 were considered significant to account for multiple testing. All analysis was done 
using SAS 9.4. 
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3.0  RESULTS 
 PRE-MATCHING RESULTS 
The total unmatched sample included 10,532,920 inpatient entries composing 1,822 IUD 
insertions, 613 IUD removals, and 10,530,485 controls with no IUD procedures. Figure 3 is a 
CONSORT chart showing how the sample population was formed. The distribution of the sample 
population for baseline characteristics is shown in Table 5. Overall, the removal group and no IUD 
procedure groups appeared to be more similar to each other than the IUD insertion group, though 
all pair-wise comparisons of the groups are statistically different except for length of stay and 
quarter of discharge for the comparisons between IUD removal vs. no IUD procedure and IUD 
removal vs. IUD insertion. Women who had an IUD inserted had the youngest mean age (27.9 
years) and women without an IUD procedure had the oldest mean age (37.5 years). Women who 
had no IUD procedure or an IUD removed were more likely to be White (58.43% and 48.97% 
respectively) while women with an IUD inserted were more likely to be Hispanic (41.19%). Rates 
of insertion of an IUD increased each year from 6% in 2010 to 34% in 2014. Rates of no IUD 
procedure decreased slightly with subsequent years from 21% in 2010 to 19% in 2014. The average 
length of stay was highest among women without an IUD procedure (3.8 days) compared to 
women with an IUD removed or inserted (both 3.3 days), though only the difference between 
having an IUD inserted and having no IUD procedure reached statistical significance. Almost all 
(93%) of the women with an IUD inserted had a child delivery code, but this was much less 
frequent in women with an IUD removed or no IUD procedure (19% and 4% respectively). Rates 
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of IUD insertion and removal increased with quarter of the year (from around 20% to around 30%) 
while rates of no IUD procedure were largely the same by quarter (25%).  
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Figure 3. CONOSRT chart showing how both the full, pre-matched sample and matched samples were formed. 
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Table 5.  Factors of interest potentially related to IUD status. 
  
No IUD 
Procedure 
n (%) 
(N=10,530,485) 
Insertion 
n (%) 
(n=1,822) 
Removal 
n (%) 
(n=613) 
Removal vs 
No IUD 
Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal 
vs 
Insertion 
p-value  
Age <21 Years 825,753 (8) 242 (13) 30 (5) <0.001** <0.001** <0.001**  
21-30 
Years 
3,012,709 (29) 938 (51) 180 (29)  
  
 
31-40 
Years 
2,483,019 (24) 574 (32) 211 (34)  
  
 
41-50 
Years 
1,823,764 (17) 59 (3) 153 (25)  
  
 
>50 Years 2,385,240 (23) 9 (0.5) 29 (6)  
  
Age Mean (SD) 37.5 (12.8) 27.9 (6.7) 35.6 
(9.9) 
<0.001** <0.001** <0.001** 
    
  
  
Race White 5,682,942 (58) 441 (25) 284 (49) <0.001** <0.001** <0.001**  
Black 1,808,435 (19) 376 (21) 189 (17)  
  
 
Hispanic 1,489,351 (15) 732 (41) 150 (26)  
  
 
Asian 310,023 (3) 85 (5) 25 (4)  
  
 
Native 7,7016 (1) 30 (2) 3 (1)  
  
 
Other 358,691 (4) 113 (6) 22 (4)  
  
    
  
  
Year of 
Admission 
 
2010 2,224,264 (21) 122 (6) 37 (6) <0.001** <0.001** <0.001** 
 
2011 2,262,023 (21) 172 (9) 174 (28)  
  
 
2012 2,062,754 (20) 414 (23) 130 (21)  
  
 
2013 1,995,612 (19) 498 (27) 144 (23)  
  
 
2014 1,985,832 (19) 626 (34) 128 (21)  
  
    
  
  
Length of 
Stay 
Mean (SD) 3.8 (5.3) 3.3 (8.4) 3.3 (5.6) 0.05* <0.001* 0.88 
    
  
  
Child 
Delivery 
Codes 
Yes 4,245,136 (40) 1694 (93) 116 (19) <0.001** <0.001** <0.001** 
    
  
  
Quarter of 
Discharge 
January-
March 
2,582,110 (25) 375 (21) 146 (24) 0.05* <0.001** 0.32 
 
April-June 2,625,705 (25) 413 (23) 139 (23)  
  
 
July-
September 
2,700,559 (26) 440 (24) 147 (24)  
  
 
October-
December 
2,606,490 (25) 592 (33) 181 (30)  
  
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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The prevalence of the comorbidities of interest by IUD status group are shown in Table 6. 
The percentage of patients with each comorbidity differed by IUD group with the exception of 
allergy and combined category of dermatitis/ eczema/ allergic urticaria. Comparison between 
women with no IUD procedure and those with removal of an IUD revealed significant differences 
in rates for hypertension, cardiovascular disease, peripheral vascular disease, and all endometriosis 
categories. Women with an IUD removed had a lower prevalence for vascular diseases 
(hypertension (12% vs. 23%, p>0.001), cardiovascular disease (6% vs. 14%, p>0.001), and 
peripheral vascular disease (5% vs. 10%, p>0.001)), but a higher prevalence for the endometriosis 
categories (7% vs. 1% for overall endometriosis, 5% vs. 0.4% for endometriosis of the uterus, and 
2% vs. 1% for non-uterine endometriosis, p>0.001 for all three categories). There were also 
significant differences between women with no IUD procedure and those with the insertion of an 
IUD for most comorbidities of interest except allergy, dermatitis/eczema/allergic urticaria, 
endometriosis of the uterus, and non-uterine endometriosis with the insertion of an IUD showing 
a lower prevalence for each disease. The prevalence of hypertension was 3% among women with 
an IUD inserted compared to 23% in women with no IUD procedure (p<0.001). Women with an 
IUD inserted had a prevalence of 3% for cardiovascular disease compared to 14% in women 
without an IUD procedure (p<0.001). The prevalence of cerebrovascular disease was 0.3% in 
women with an IUD inserted compared to women with no IUD procedure (2%, p<0.001). The 
prevalence of peripheral vascular disease was 5% among women with an IUD inserted compared 
to 10% in women without an IUD procedure (p<0.001). Women with an IUD inserted had a 
prevalence of auto-immune disorders of 1% while women without an IUD procedure had a 
prevalence of 3% (p<0.001 respectively). The prevalence of endometriosis in women with an IUD 
inserted was 0.3% and 1% in women with no IUD procedure (p=0.01). The prevalence of both 
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rheumatoid arthritis and lupus in women with an IUD inserted was 0.4% but 1%  in women with 
an IUD removed (p=0.001).  Prevalence of disease was similar between women with the insertion 
of an IUD and the removal of an IUD except for hypertension (12% vs. 3%, p>0.001), 
cerebrovascular (2% vs. 0.3%, p>0.001), and all the endometriosis categories (7% vs. 0.3% for 
overall endometriosis, 5% vs. 0.05% for endometriosis of the uterus, and 2% vs. 0.3% for non-
uterine endometriosis, p>0.001 for all three categories). The prevalence of hypertension, 
cerebrovascular disease, and all endometriosis categories was lower in the insertion group 
compared to the removal group. 
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Table 6. Unmatched distribution of diseases of interest by IUD group. 
 
No IUD 
Procedure 
n (%) 
(N=10,530,485) 
Insertion 
n (%) 
(N=1822) 
Removal 
n (%) 
(N=613) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal vs 
Insertion 
 p-value 
Vascular 
  
  
  
Hypertension 2,405,679 (23) 59 (3) 73 (12) <0.001** <0.001** <0.001** 
Cardiovascular 1,488,003 (14) 75 (4) 34 (6) <0.001** <0.001** 0.15 
Cerebrovascular 223,097 (2) 6 (0.3) 10 (2) 0.40 <0.001 <0.001** 
Peripheral 
Vascular 
1,037,744 (10) 82 (5) 33 (5) <0.001** <0.001** 0.37 
Auto-immune 
  
  
  
Auto-immune 335,323 (3) 16 (1) 11 (2) 0.05* <0.001** 0.06 
Allergy 1,715,429 (16) 271 (15) 100 (16) 0.99 0.10 0.39 
Rheumatoid 
Arthritis 
127,822 (1) 7 (0.4) 6 (1) 0.60 0.001** 0.08 
Lupus 144,151 (1) 7 (0.4) 4 (1) 0.13 <0.001** 0.39 
Dermatitis/Eczema
/Allergic Urticaria 
56,800 (1) 5 (0.3) 3 (0.5) 0.87 0.12 0.42 
Endometriosis 
  
  
  
Endometriosis 90,752 (1) 9 (0.3) 44 (7) <0.001** 0.01* <0.001** 
Endometriosis of 
the Uterus 
41,083 (0.4) 1 (0.05) 32 (5) <0.001** 0.23 <0.001** 
Non-Uterine 
Endometriosis 
56,317 (1) 6 (0.3) 15 (2) <0.001** 0.02* <0.001** 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
 
The distribution of propensity scores by IUD group before matching is shown in Figure 4. 
In order to improve the visualization of distribution which was initially affected by some outliers, 
the propensity scores were cut off at 0.002 which is the 99 percentile for insertion group which 
had the highest 99 percentile. Comparing the minimum, Q1, median, Q3, and maximum values 
across IUD status group, all but the median values were at least one order of magnitude different, 
indicating that the three groups are not comparable. 
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The distribution of the propensity scores was cut off at 0.002. 
 
Figure 4. Pre-matching distribution of probability of an IUD-related ICD-9 code. 
 POST-MATCHING RESULTS 
Because baseline characteristics were different between the groups, propensity matching was 
performed as an attempt to make the three groups (no IUD procedure, IUD removal, and IUD 
insertion) more comparable. After matching, 417 triplets were identified. The number of triplets 
was limited by the number of removals as it was the smallest group (n=613) before matching. The 
minimized sample size was expected to help prevent the study from being overpowered 
Min=4.32x10-8, Q1=4.12x10-6, Med=1.38x10-4, Q3=3.19x10-4, Max=3.58x10-2 
Min=5.74x10-6, Q1=3.82x10-4, Med=6.80x10-4, Q3=1.10x10-3, Max=3.33x10-3 
Min=4.67x10-6, Q1=8.98x10-5, Med=1.76x10-4, Q3=3.59x10-4, Max=2.12x10-3 
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(specifically, from the high number of controls, n=10,530,485) and ensure that significant results 
will be more likely to be clinically meaningful and reduce the impact of confounding. Some 
women with an IUD removed were not matched due to the inability to find a woman with an IUD 
inserted that had a similar propensity score.  
As expected, the women without IUD procedures, insertion of an IUD and the removal of 
an IUD became more similar to each other after the propensity matching (Table 7). After matching, 
there was no difference in rates of any baseline factors between women with no IUD procedure 
and women with removal of an IUD. Statistically significant differences remained for all factors 
of interest between women without an IUD procedure and women with the insertion of an IUD, 
with the exception of length of stay and quarter of discharge. Women with the removal of an IUD 
and those with the insertion of an IUD are also different in all factors except for length of stay 
(though the results became more similar than they were initially). When comparing the three IUD 
groups, statistically significant differences were maintained for all factors except for length of stay 
and quarter of discharge (result not shown).  
Compared to the unmatched data in Table 5, the matched subpopulations were younger for 
no IUD procedure (37.5 years vs. 33.3 years) and IUD removal (35.6 years vs. 33.3 years) but 
older for IUD insertion (35.6 years vs. 28.5 years). There were lower rates of Whites among 
women with no IUD procedure (58% vs. 38%) and an IUD removal (49% vs. 37%) and higher 
rates in women with an IUD insertion (25% vs 49%). There were higher rates of Hispanics in 
women with no IUD procedure (15% vs. 33%) and lower rates in women with an IUD removal 
(26% vs. 34%) or IUD insertion (26% vs. 19%). Within the matched sample, rates of not having 
an IUD procedure had a distinct increase with year of admission (from 4% to 24%), while rates of 
insertion were relatively constant from year to year (around 20%). Length of stay, child delivery 
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codes, and quarter of discharge after matching followed patterns similar to the pre-matching trends. 
When comparing the matched data to the unmatched data, the removal and no IUD procedure in 
the matched group were much more similar to each other, but the insertion group remained very 
different from both the removal and no IUD procedure groups, indicating the need for further 
adjustment in the analysis. The fact that the removal and no IUD procedure groups were very 
similar is an indication that the propensity score matching was successful. 
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Table 7. Baseline characteristics that may be related to IUD group after propensity matching.   
No IUD 
Procedure 
n (%) 
(N=417) 
Insertion 
n (%) 
(n=417) 
Removal 
n (%) 
(n=417) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal vs 
Insertion 
p-value  
Age <21 Years 28 (7) 70 (17) 27 (6) 1.0 <0.001** <0.001**  
21-30 Years 149 (36) 204 (49) 145 (35)  
  
 
31-40 Years 150 (36) 101 (24) 153 (37)  
  
 
41-50 Years 86 (21) 33 (8) 88 (21)  
  
 
>51 Years 4 (1) 9 (2) 4 (1)  
  
    
  
  
Age Mean (SD) 33.3 (8.9) 28.5 (8.3) 33.3 (8.6) 0.91 <0.001** <0.001**     
  
  
Race White 157 (38) 203 (49) 154 (37) 0.87 <0.001** <0.001**  
Black 82 (20) 86 (21) 80 (19)  
  
 
Hispanic 139 (33) 81 (19) 142 (34)  
  
 
Asian 15 (4) 17 (4) 19 (5)  
  
 
Native 5 (1) 2 (0.5) 2 (0.5)  
  
 
Other 19 (5) 28 (7) 20 (5)  
  
    
  
  
Year of 
Admission 
2010 17 (4) 82 (20) 17 (4) 1.0 <0.001** <0.001** 
 
2011 93 (22) 83 (20) 91 (22)  
  
 
2012 92 (22) 81 (19) 93 (22)  
  
 
2013 113 (27) 76 (18) 115 (28)  
  
 
2014 102 (24) 95 (23) 101 (24)  
  
    
  
  
Length of 
Stay 
Mean (SD) 3.0 (3.2) 3.0 (3.7) 3.4 (6.2) 0.25 0.88 0.31 
    
  
  
Child 
Delivery 
Codes 
Yes 113 (27) 328 (79) 110 (26) 0.81 <0.001** <0.001** 
    
  
  
Quarter of 
Discharge 
January-
March 
92 (22) 69 (17) 94 (23) 0.96 0.03* 0.02* 
 
April-June 94 (23) 96 (23) 94 (23)  
  
 
July-
September 
103 (25) 88 (21) 104 (25)  
  
 
October-
December 
128 (31) 164 (39) 125 (30)  
  
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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The distribution of the propensity scores by IUD group after matching are shown in Figure 
5. Compared to Figure 4, the distributions of propensity scores for all three IUD groups were much 
more similar to each other compared to the pre-matching distribution with the minimum, Q1, 
median, Q3, and maximum values all within one order of magnitude of each other when comparing 
across IUD status group. This is another indication that the matching was successful. 
 
 
 
 
 
Figure 5. Post-matching distribution of propensity scores. 
 
 
Min=5.60x10-6, Q1=1.66x10-4, Med=2.63x10-4, Q3=4.93x10-4, Max=2.12x10-3 
Min=5.74x10-6, Q1=1.78x10-4, Med=2.55x10-4, Q3=4.93 x10-4, Max=2.12 x10-3 
Min=5.60x10-6, Q1=1.66x10-4, Med=2.63x10-4, Q3=4.93x10-4, Max=2.12x10-3 
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Post-matching results comparing the IUD status groups to the comorbidities of interest are 
shown in Table 8. Significant differences between the subpopulations with removal of an IUD and 
not having an IUD procedure remained for hypertension, cardiovascular disease, peripheral 
vascular disease, overall endometriosis, and endometriosis of the uterus. There was a lower 
prevalence of vascular diseases (9% vs. 17% in hypertension, p<0.001, 4% vs. 11% in 
cardiovascular disease, p<0.001, 4% vs. 9% in peripheral vascular disease, p=0.002), but an 
increased prevalence of all endometriosis categories in women with an IUD removed (7% vs. 2% 
in overall endometriosis, p<0.001, and 5% vs. 1% in endometriosis of the uterus, p>0.001). 
Statistically significant differences in the subpopulations with an IUD insertion compared to 
women without an IUD procedure showed a decreased prevalence of hypertension (6% vs 17%, 
p>0.001) and cardiovascular disease (1% vs. 2%, p=0.002).  
Unlike in the comparison of baseline characteristics (Table 7), when looking at the 
comorbidities, IUD insertion group was fairly similar to the IUD removal and no IUD procedure 
groups, but the IUD removal and no IUD procedure groups were different from each other. The 
only comorbidities with different prevalences between IUD groups were overall endometriosis and 
endometriosis of the uterus with prevalences being highest when IUDs are removed (7% and 5% 
respectively) and lowest among women with IUDs inserted (1% and 0.2% respectively, p<0.001 
for both. Disease prevalences within each IUD status group were relatively similar between the 
pre-matched and matched samples.  
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Table 8. Distribution of diseases of interest after propensity matching. 
 
No IUD 
Procedure 
n (%) 
(N=417) 
Insertion 
n (%) 
(n=417) 
Removal 
n (%) 
(n=417) 
Removal vs 
No IUD Proc 
p-value 
Insertion vs 
No IUD Proc 
p-value  
Removal vs 
Insertion  
p-value  
Vascular 
  
  
  
Hypertension 71 (17) 26 (6) 37 (9) <0.001** <0.001** 0.15 
Cardiovascular 45 (11) 21 (5) 17 (4) <0.001** 0.002** 0.51 
Cerebrovascular 8 (2) 3 (1) 8 (2) 1.0 0.13 0.13 
Peripheral Vascular 38 (9) 24 (6) 16 (4) 0.002** 0.06 0.19 
Auto-immune 
  
  
  
Auto-immune 12 (3) 4 (1) 4 (1) 0.04* 0.04* 1.0 
Allergy 62 (15) 73 (18) 62 (15) 1.0 0.30 0.3 
Rheumatoid 
Arthritis 
5 (1) 1 (0.2) 3 (1) 0.73 0.10 0.62 
Lupus 4 (1) 2 (0.5) 1 (0.2) 0.37 0.69 1.0 
Dermatitis/Eczema/
Allergic Urticaria 
2 (0.5) 1 (0.2) 2 (0.5) 1.0 1.0 1.0 
Endometriosis 
  
  
  
Endometriosis 8 (2) 3 (1) 30 (7) <0.001** 0.13 <0.001** 
Endometriosis of 
the Uterus 
4 (1) 1 (0.2) 22 (5) <0.001** 0.37 <0.001** 
Non-Uterine 
Endometriosis 
4 (1) 3 (0.7) 11 (3) 0.13 0.73 0.03* 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
 
 
 
 
The results of the conditional logistic regression models are shown in Tables 9-11. Model 
1 is unadjusted, Model 2 adjusts for age, year, and child delivery code, and Model 3 adjusts for 
covariates from Model 2 along with race. Estimates for cerebrovascular disease, rheumatoid 
arthritis, dermatitis/eczema/allergic urticaria, and endometriosis of the uterus were not adjusted 
for child delivery code because it made the models unstable. Lupus was not included in the table 
because both adjusted models were unstable. The effect of IUD group on the comorbidities 
significantly varied across IUD status group for hypertension, cardiovascular disease, peripheral 
vascular disease, and endometriosis in all three models (Tables 9 and 11). Endometriosis of the 
uterus was significant in the unadjusted model and borderline significant in both adjusted models 
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(Table 11). In Table 10, after adjustment, the relationship between IUD group and autoimmune 
disorders and allergies was borderline significant (p=0.03 and 0.04 respectively). The estimates 
for model 2 and model 3 are nearly identical, indicating limited confounding by race. 
The comparisons between women having an IUD removed and women without an IUD 
procedure are the main comparisons of interest and they followed similar significance patterns as 
the models looking at IUD status group overall. In Table 9, the results were similar between the 
three models with hypertension (Model 3 OR=2.3, p=0.004), cardiovascular disease (Model 3 
OR=2.9, p=0.002), and peripheral vascular disease (Model 3 OR=2.9, p=0.002) showing a 
significant association with decreased likelihood among women with an IUD removed compared 
to not having an IUD procedure. The removal of an IUD had an increased association on overall 
endometriosis (Model 3 OR=0.13, p=0.004). Endometriosis of the uterus showed a borderline 
association between IUD removal compared to not having an IUD procedure (Model 3 OR=0.04, 
p=0.02). When compared to having an IUD inserted, there was a decreased relationship in 
cardiovascular disease (Model 3 OR=3.9, p=0.004) and peripheral vascular disease (Model 3 
OR=4.8, p=0.001) and an increased relationship seen between overall endometriosis (Model 3 
OR=0.10, p=0.006) and endometriosis of the uterus (Model 3 OR=0.06, p=0.03) in having an IUD 
removed. 
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Table 9. Results of conditional logistic regression models for vascular diseases. 
  
Model 1 Model 2 Model 3   
OR 95% 
CI 
p-value OR 95% 
CI 
p-value OR 95% 
CI 
p-value 
Hypertension IUD Group <0.001 
** 
  
0.006 
** 
  
0.007 ** 
 
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.68 0.40, 
1.1 
0.15 2.5 1.2, 
5.5 
0.02 * 2.5 1.2, 
5.6 
0.02 * 
 
No IUD 
Procedure 
2.2 1.4, 
3.3 
<0.001 
** 
2.4 1.3, 
4.2 
0.003 
** 
2.3 1.3, 
4.1 
0.004 ** 
           
Cardiovascular IUD Group <0.001 
** 
  
0.004 
** 
  
0.003 ** 
 
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 1.3 0.65, 
2.4 
0.50 3.6 1.5, 
8.9 
0.005 
** 
3.9 1.6, 
9.9 
0.004 ** 
 
No IUD 
Procedure 
2.9 1.6, 
5.3 
<0.001 
** 
2.9 1.5, 
8.9 
0.002 
** 
2.9 1.5, 
5.7 
0.002 ** 
           
Cerebrovascular*** IUD Group 0.28   0.36   0.36  
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.36 0.09, 
1.4 
0.14 0.36 0.09, 
1.5 
0.15 0.36 009, 
1.5 
0.15 
 
No IUD 
Procedure 
1.0 0.36, 
2.8 
1.0 0.71 0.21, 
2.4 
0.58 0.71 0.21, 
2.4 
0.58 
           
Peripheral Vascular IUD Group <0.001 
** 
  
0.001 
** 
  
0.002 ** 
 
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 1.5 0.80, 
2.9 
0.20 5.0 2.0, 
12.8 
<0.001 
** 
4.8 1.9, 
12.3 
0.001 ** 
 
No IUD 
Procedure 
2.5 1.4, 
4.6 
0.003 
** 
2.9 1.5, 
5.8 
0.002 
** 
2.9 15, 
5.7 
0.002 ** 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
Model 1: Unadjusted 
Model 2: Age, year, and child delivery code adjusted 
Model 3:   Model 2 plus race 
*** Cerebrovascular disease not adjusted for child delivery code 
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Table 10. Results of conditional logistic regression models for allergic/immune conditions. 
  
Model 1 Model 2 Model 3   
OR 95% 
CI 
p-value OR 95% 
CI 
p-
value 
OR 95% CI p-
value 
Autoimmune IUD Group 0.06 
  
0.08 
  
0.03 *  
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 1.0 0.25, 
4.0 
1.0 1.4 0.28, 
7.5 
0.67 1.1 0.21, 5.9 0.90 
 
No IUD 
Procedure 
3.0 0.97, 
9.3 
0.06 3.9 1.1, 
14.4 
0.04 6.6 1.3, 34.8 0.03 * 
           
Allergies IUD Group 0.48 
  
0.02 * 
  
0.04 *  
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 1.2 0.84, 
1.8 
0.30 1.8 1.2, 
2.9 
0.01 
** 
1.8 1.1, 2.8 0.02 * 
 
No IUD 
Procedure 
1.0 0.8, 
1.5 
1.0 1.1 0.72, 
1.6 
0.77 1.1 0.71, 1.6 0.78 
           
Rheumatoid 
Arthritis*** 
IUD Group 0.32   0.23 
Not Estimable 
 
Removal 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.33 0.04, 
3.2 
0.34 0.46 0.03, 7.2 0.58  
No IUD 
Procedure 
1.7 0.40, 
7.0 
0.48 0.37 0.34, 40.9 0.28      
      
Dermatitis/Eczema/
Allergic 
Urticaria*** 
IUD Group 0.83 
  0.69 
Not Estimable 
 
Removal 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.50 0.05, 
5.5 
0.57 0.69 0.04, 
11.9 
0.80 
 
No IUD 
Procedure 
1.0 0.14, 
7.1 
1.0 2.0 0.19, 
20.3 
0.57 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
Model 1: Unadjusted 
Model 2: Age, year, and child delivery code adjusted 
Model 3:   Model 2 plus race 
*** Rheumatoid arthritis and dermatitis/eczema/allergic urticaria not adjusted for child delivery code 
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Table 11. Results of conditional logistic regression models for endometriosis. 
  
Model 1 Model 2 Model 3   
OR 95% 
CI 
p-value OR 95% 
CI 
p-value OR 95% 
CI 
p-
value 
Endometriosis 
         
Endometriosis IUD Group <0.001 
** 
  
0.002 ** 
  
0.002 
**  
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.25 0.11, 
0.56 
<0.001 
** 
0.10 0.02, 
0.52 
0.006 ** 0.10 0.02, 
0.52 
0.006 
**  
No IUD 
Procedure 
0.25 0.11, 
0.56 
<0.001 
** 
0.19 0.06, 
0.57 
0.003 ** 0.13 0.03, 
0.53 
0.004 
**            
Endometriosis of 
the Uterus*** 
IUD Group <0.001 
**   0.02*   0.02*  
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.04 0.01, 
0.29 
0.002 
** 
0.08 0.008, 
0.74 
0.03* 0.06 0.005, 
0.7 
0.03* 
 
No IUD 
Procedure 
0.15 0.05, 
0.48 
0.001 
** 
0.08 0.009, 
0.80 
0.003* 0.04 0.002, 
0.62 
0.02* 
           
Non-Uterine 
Endometriosis 
IUD Group 0.08 
  
0.11 
  
0.18 
 
Removal 1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref  
Insertion 0.25 0.07, 
0.9 
0.04 * 0.23 0.04, 
1.4 
0.11 0.04  0.001, 
1.4 
0.07 
 
No IUD 
Procedure 
0.43 0.14, 
1.3 
0.13 0.36 0.09, 
1.4 
0.14 0.07 0.003, 
1.5 
0.09 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
Model 1: Unadjusted 
Model 2: Age, year, and child delivery code adjusted 
Model 3:   Model 2 plus race 
*** Endometriosis of the uterus not adjusted for child delivery code 
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 RACE ANALYSIS 
Tables 12-14 show the distribution of the comorbid diseases by race. The distribution of 
races other than White and Black in the matched sample for no IUD procedure and removal was: 
33% Hispanic, 4% Asian, 1% Native, and 5% other. It is important to note that due to too few 
cases of certain comorbidities, the race-stratified analysis was not performed for rheumatoid 
arthritis, lupus, and dermatitis/eczema/allergic urticaria. The significance patterns for disease by 
race generally reflect the patterns in the unstratified matched sample. 
White women with no IUD procedure had a higher prevalence of hypertension (17%) 
compared to women with an IUD inserted (7%, p=0.004) or removed (3%, p<0.001) (Table 12). 
The only significant difference in prevalence of hypertension by IUD status group in Black women 
was a higher prevalence in women with no IUD procedure compared to women with an IUD 
inserted (23% vs. 9%, p=0.01) (Table 13). Women in the other race category who had no IUD 
procedure had a higher prevalence of hypertension (14%) compared to women with an IUD 
inserted (2%, p<0.001), and women with an IUD inserted also had a lower prevalence compared 
to women with an IUD removed (10%, p=0.007) (Table 14).  
There were no significant differences in prevalence of cardiovascular disease in White 
women by IUD status group (Table 12). Among Blacks, the only significant difference in 
prevalence of cardiovascular disease was that women with an IUD removed had a lower prevalence 
(4%) compared to women without an IUD procedure (20%, p=0.0020) (Table 13). Among other 
races, women with an IUD removed had a lower prevalence of cardiovascular disease (3%) 
compared to women without an IUD (11%, p=0.006), and women without an IUD also had a higher 
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prevalence of cardiovascular disease compared to women with an IUD inserted (2%, p=0.005) 
(Table 14). 
Women in the other race category who had an IUD removed had a higher prevalence of 
endometriosis of the uterus (5%) compared to women with an IUD inserted or women with no 
IUD procedure (0%, p=0.007 for both). This pattern is also seen among women with 
endometriosis, though only the difference between women with an IUD removed and no IUD 
procedure reached statistical significance (Table 14). This pattern is also seen in non-uterine 
endometriosis among women in the other race category as well as all three endometriosis 
categories for White women and Black women, though they fail to reach statistical significance 
(Tables 12 and 13). 
The distribution of baseline characteristics by race are shown in Appendix A. The 
significance patterns for each race group among the baseline characteristics reflect those in Table 
7: the removal and no IUD procedure groups being very similar and the insertion group being 
different from both, except for length of stay and quarter of discharge.  
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Table 12. Distribution of comorbid diseases of interest in Whites. 
 
No IUD 
Procedure 
n (%) 
(N=157) 
Insertion 
n (%) 
(N=203) 
Removal 
n (%) 
(N=154) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal 
vs 
Insertion 
p-value  
Vascular 
  
  
  
Hypertension 27(17) 15(7) 5(3) <0.001** 0.004** 0.09 
Cardiovascular 10(6) 11(5) 8(5) 0.66 0.70 0.93 
Cerebrovascular 2(1) 2(1) 5(3) 0.28 1.0 0.15 
Peripheral Vascular 14(9) 13(6) 6(4) 0.07 0.37 0.30 
Allergy 
  
  
  
Auto-immune 5(3) 3(1) 1(1) 0.21 0.30 0.64 
Allergy 20(13) 40(20) 22(14) 0.69 0.08 0.18 
Rheumatoid Arthritis 2(1) 1(0.5) 1(1) 1.0 0.58 1.0 
Lupus 0 1(0.5) 0 - 1.0 1.0 
Dermatitis/Eczema/Allergic 
Urticaria 
0 0 0 - - - 
Endometriosis 
  
  
  
Endometriosis 5(3) 2(1) 17(11) 0.007** 0.25 <0.001** 
Endometriosis of the Uterus 4(3) 1(0.5) 12(8) 0.04* 0.17 <0.001** 
Non-Uterine Endometriosis 2(1) 2(1) 7(5) 0.10 1.0 0.04* 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
 
 
 
 
 
 
 
 
 
 
42 
 
Table 13. Distribution of comorbid diseases of interest in Blacks. 
 
No IUD 
Procedure 
n (%) (N=82) 
Insertion 
n (%) 
(N=86) 
Removal 
n (%) 
(N=80) 
Removal vs 
No IUD 
Proc 
p-value 
Insertion 
vs No IUD 
Proc  
p-value  
Removal vs 
Insertion  
p-value  
Vascular 
  
  
  
Hypertension 19(23) 8(9) 13(16) 0.27 0.01* 0.18 
Cardiovascular 16(20) 7(8) 3(4) 0.002** 0.03* 0.33 
Cerebrovascular 1(1) 1(1) 0 1.0 1.0 1.0 
Peripheral Vascular 9(11) 6(7) 5(6) 0.28 0.36 0.85 
Allergy 
  
  
  
Auto-immune 4(5) 1(1) 2(3) 0.68 0.20 0.61 
Allergy 21(26) 18(21) 19(24) 0.78 0.47 0.66 
Rheumatoid 
Arthritis 
2(2) 0 1(1) 1.0 0.24 0.48 
Lupus 3(4) 1(1) 1(1) 0.62 0.36 1.0 
Dermatitis/Eczema/
Allergic Urticaria 
1(1) 0 1(1) 1.0 0.49 0.48 
Endometriosis 
  
  
  
Endometriosis 1(1) 0 2(3) 0.62 0.49 0.23 
Endometriosis of 
the Uterus 
0 0 2(3) 0.24 - 0.23 
Non-Uterine 
Endometriosis 
1(1) 0 0 1.0 0.49 - 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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Table 14. Distribution of comorbid diseases of interest in other races. 
 
No IUD 
Procedure 
n (%) 
(N=179) 
Insertion 
n (%) 
(N=128) 
Removal 
n (%) 
(N=183) 
Removal vs 
No IUD 
Proc  
p-value 
Insertion 
vs No IUD 
Proc 
p-value  
Removal vs 
Insertion 
p-value  
Vascular 
  
  
  
Hypertension 25(14) 3(2) 19(10) 0.29 <0.001** 0.007** 
Cardiovascular 19(11) 3(2) 6(3) 0.006** 0.005** 0.74 
Cerebrovascular 5(3) 0 3(2) 0.50 0.08 0.27 
Peripheral Vascular 15(8) 5(4) 5(3) 0.02* 0.11 0.75 
Allergy 
  
  
  
Auto-immune 3(2) 0 1(1) 0.37 0.27 1.0 
Allergy 21(12) 15(12) 21(11) 0.93 0.98 0.95 
Rheumatoid 
Arthritis 
1(1) 0 1(1) 1.0 1.0 1.0 
Lupus 1(1) 0 0 0.49 1.0 - 
Dermatitis/Eczema
/Allergic Urticaria 
1(1) 0 1(1) 1.0 1.0 1.0 
Endometriosis 
  
  
  
Endometriosis 2(1) 1(1) 11(6) 0.01* 1.0 0.02* 
Endometriosis of 
the Uterus 
0 0 8(5) 0.007** - 0.02* 
Non-Uterine 
Endometriosis 
2(1) 1(1) 4(2) 0.69 1.0 0.65 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
 
 
 
As shown in table 15, the overall effect of IUD status group on odds of comorbid disease 
by race was further analyzed based on the interaction between race and IUD status group. Analysis 
for cerebrovascular disease, rheumatoid arthritis, lupus, dermatitis/eczema/allergic urticaria, and 
endometriosis of the uterus were not reported in this table due to the small number of cases for 
each of these diseases. Unadjusted models were used for this analysis due to small samples and 
low event rates. In order to obtain estimable models, only the comparison between IUD removals 
to no IUD procedure were analyzed. We then tested for a statistical interaction between IUD status 
group (specifically IUD removal vs. no IUD procedure) and race. There were significant effects 
when comparing the IUD removal and no IUD procedure groups among Whites for hypertension 
(OR=0.007, 95% CI 0.01, 0.51) and endometriosis (OR=13.0, 95% CI 1.7, 99.4). There were no 
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significant associations among the Blacks or other race. None of the interactions tested were 
significant. Due to the low numbers of people in each category, results for many of the models and 
the interaction estimate were not able to be estimated. When testing the association between race 
and IUD status group in a chi-square test by comorbidity, the only significant relationship found 
was in women with hypertension (p=0.0026, results not shown). This gives some evidence for an 
interaction between race and IUD status on hypertension. 
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Table 15.  Race and IUD group interaction on comorbid disease. 
Outcome 
 
White Black Other race Inter   
OR 95% 
CI 
p-
value 
OR 95% 
CI 
p-
value 
OR 95% 
CI 
p-
value 
p-
value 
Vascular 
           
Hypertension IUD Group 
       
0.15  
No IUD 
Procedure 
1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref 
 
 
Removal 0.07 0.01, 
0.51 
0.009
** 
0.33 0.04, 
3.2 
0.34 0.91 0.39, 
2.1 
0.83 
 
            
Cardiovascular IUD Group 
 
Not Estimable 
   
-  
No IUD 
Procedure 
1.0 Ref Ref 1.0 Ref Ref 
 
 
Removal 0.67 0.19, 
2.4 
0.53 0.13 0.02, 
1.0 
0.05 
 
            
Peripheral 
Vascular 
IUD Group 
       
0.98 
 
No IUD 
Procedure 
1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref 
 
 
Removal 0.50 0.09, 
2.7 
0.42 0.50 0.05, 
5.5 
0.57 0.29 0.06, 
1.4 
0.12 
 
            
Allergy 
           
Autoimmune IUD 
Group 
Not Estimable Not Estimable 
   
- 
 
No IUD 
Procedure 
1.0 Ref Ref 
 
 
Removal 1.0 0.06, 
16.0 
1.0 
 
            
Allergies IUD Group 
       
0.27  
No IUD 
Procedure 
1.0 Ref Ref 1.0 Ref Ref 1.0 Ref Ref 
 
 
Removal 1.0 0.38, 
2.7 
1.0 0.20 0.02, 
1.7 
0.14 1.1 0.45, 
2.7 
0.82 
 
Endometriosis 
           
Endometriosis IUD Group 
 
Not Estimable 
   
-  
No IUD 
Procedure 
1.0 Ref Ref 1.0 Ref Ref 
 
 
Removal 13.0 1.7, 
99.4 
0.01*
* 
3.0 0.31, 
28.8 
0.34 
 
            
Non-Uterine 
Endometriosis 
IUD 
Group 
Not Estimable Not Estimable 
   
- 
 
No IUD 
Procedure 
1.0 Ref Ref 
 
 
Removal 2.0 0.18, 
22.1 
0.57 
 
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing.  
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4.0  DISCUSSION 
This study investigated if pre-specified comorbidities are associated with the removal of an IUD 
in an inpatient population. We also estimated if the effect of IUD status on the outcomes potentially 
differed by race. Within the triplet matched population, decreased likelihood of hypertension, 
cardiovascular disease, peripheral vascular disease, and higher likelihood of endometriosis were 
related to the removal of an IUD compared to women without an IUD procedure within both 
unadjusted and adjusted models. While the trends in significance levels varied in race-stratified 
analyses, there were no significant interactions between race and IUD status. This study helps 
build on to knowledge about IUD-related adverse events and will have an increasing public health 
impact as IUDs continue to gain popularity in the US.  
While many demographic differences remained after propensity score matching between 
IUD removal and IUD insertion for baseline characteristics, the matching eliminated many of the 
measured differences between the IUD removal and no IUD procedure groups in baseline 
characteristics and between IUD removal and IUD insertion for comorbidities of interest.  
 DISCUSSION OF MAIN RESULTS 
The conditional logistic regression models showed a decreased likelihood of hypertension, 
cardiovascular disease, and peripheral vascular disease in women with an IUD removed compared 
to women with no IUD procedure.  These models also estimated an increased likelihood of overall 
endometriosis and endometriosis of the uterus in women with an IUD removed compared to 
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women with an IUD inserted or no IUD procedure within an inpatient population. While the race-
stratified analysis varied in significance level trends, the results of the race-stratified analysis did 
show a statistical interaction between IUD status and any of the comorbidities of interest. 
More of a difference in the outcomes is seen in the unadjusted and adjusted models (Tables 
9-11) when comparing the IUD insertion to IUD removal groups than when comparing the IUD 
removal to the no IUD procedure group. This is expected because the no IUD procedure and IUD 
removal groups were very similar to each other after propensity score matching, so less adjustment 
needed to be done between the two groups. In the IUD insertion group there were statistically 
significant demographic characteristics compared to the IUD removal group after propensity score 
matching, so the adjustment in models for these characteristics had a larger impact and was more 
necessary for appropriate analysis. Unfortunately, we could not adjust for all differences in Table 
7 for all comorbidities as the models became unstable. 
4.1.1 Vascular disease results 
Our study found a significant association between having an IUD removed and a decreased 
likelihood of having hypertension, cardiovascular disease, and peripheral vascular disease 
compared to women with no IUD procedure. This study didn’t examine underlying reasons for 
this association, but there are several possibilities. 
One possible reason could be that there is a causal relationship between women who have 
IUDs and a decreased risk for these vascular diseases. The mechanism for how this would happen 
is unclear. IUDs are known to affect local areas to the insertion site, but physicians are more 
skeptical in accepting that systemic events are causally related to the IUD as there is conflicting 
literature supporting systemic effects and IUD use. 
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Another reason for the association could be unmeasured confounders. For example, 
physician’s may only want to insert IUDs in women who are healthier. Women who have an IUD 
may also be more integrated in the healthcare system as they need to have an IUD inserted in a 
physician’s office. If so, women with an IUD may engage in more preventative care and therefore 
be healthier. Because IUDs are not the most popular form of contraception in the United States, 
women who choose to have an IUD inserted may actively make healthier choices than women who 
do not have an IUD. More research needs to be done to determine the reason for the association 
between having an IUD removed and a decreased likelihood for having vascular diseases. 
4.1.2 Endometriosis results 
Women who had an IUD removed were found to be at an increased risk for overall endometriosis 
in all models and for endometriosis of the uterus in the unadjusted model compared to both women 
with an IUD inserted and no IUD procedure. Women with endometriosis are more likely to be 
admitted to the hospital with pelvic pain and are at a higher risk for wanting their IUD removed 
than women without endometriosis. Women who are hospitalized for pelvic pain may request that 
they have their IUD removed as they feel it will relieve their symptoms, though the pelvic pain 
could be independent of the IUD. Women with endometriosis who desire to use IUDs should be 
counseled on their increased risk for pelvic pain and how this pain may not be due to the IUD, but 
due to their pre-existing endometriosis. The lack of significance between endometriosis of the 
uterus in the adjusted models is likely due to a lack of power as there were only 27 cases of 
endometriosis of the uterus in the matched sample. The odds of endometriosis of the uterus was 
14 times higher in women with an IUD removed compared to women without an IUD procedure, 
indicating a clinical significance that was underpowered to reach statistical significance. 
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4.1.3 Race-stratified results 
When trying to asses an interaction between IUD status and race, no significant statistical 
interactions were detected, though the fact that the odds ratio estimates for each comorbidity vary 
by race (Table 15) indicate that there may be clinically relevant differences in comorbidity use by 
race driven by IUD use. There is also evidence that both IUD use and comorbid diseases vary by 
race26. Therefore, any findings in this area have to be viewed critically to assess the relationship 
between race, IUD status, and comorbidity. 
 STRENGTHS AND LIMITATIONS 
This study has several strengths including the propensity score matching and using a novel 
population. Some of the limitations associated with this study are being underpowered in some of 
the analyses, the fact that most IUD insertions and removals are not done in the inpatient setting, 
the difficulty in determining the best way to do propensity matching with multiple levels of 
exposure, the fact that the data source is from billing code data, and residual confounding.  
 The overall strength of this study was due to the use of propensity scores for selection of 
the appropriate controls. By using propensity scores instead of randomly choosing women who 
did not have an IUD, the controls are more similar to the cases (specifically for women with IUD 
removal vs no IUD procedure), creating more comparable groups at baseline. The fact that there 
were multiple IUD-related group categories made propensity score matching difficult. We used 
the probability of having any IUD-related code as our propensity score to allow for comparisons 
of women with both IUD removal and IUD insertion to women with no IUD procedure. In order 
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to get the most similar populations across the three groups, we implemented a 2-stage matching 
process (first matching IUD removals to IUD insertions and then taking the matched IUD removals 
and matching them to women without IUD procedures). This process worked very well for the 
IUD removal and no IUD procedure groups as after the matching they had similar baseline 
characteristics. However, this process did not work as well for the IUD insertions compared to the 
IUD removals or the no IUD procedure groups, which is likely due to the limited number of IUD 
insertions as well as inherent differences between women who get an IUD removed versus women 
who get an IUD inserted in the inpatient setting. This difference appears to be driven primarily 
through having a child delivery code as IUDs are common contraceptive choices in post-partem 
women. Another reason for this difference is due to matching within the same propensity group as 
both IUD insertion and IUD removal were classified in the IUD group when determining the 
propensity score. A way to remedy this would be to estimate the propensity scores using a 
polytomous logistic regression looking at no IUD procedure, IUD insertion, and IUD removal as 
separate categories (which, however, may not be feasible due to the uneven numbers in the IUD 
status groups). Another approach would be to rerun the propensity score analysis using the 
probability of an IUD removal. This approach may allow for the groups to be more similar to each 
other, compared to the propensity matching based on an IUD related ICD-9 code in general. 
As a result of the performed matching procedure, almost 200 IUD removal cases and 1,400 
IUD insertion cases were not matched for subsequent analysis which may have been underpowered 
for finding smaller effect sizes. However, use of propensity score matching was still a justifiable 
analytic strategy because it allowed for the study group to be more similar and therefore more 
comparable to each other. In the future, an analysis plan that can allow the population to be 
matched while allowing more of the IUD removals and IUD insertions to be included may give 
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more statistical power for identifying differences. This approach may be especially beneficial for 
outcomes such as allergic and autoimmune comorbidities (e.g., rheumatoid arthritis, lupus, and 
dermatitis/ eczema/ allergic urticaria) that did not have enough cases in the current propensity 
matched sample to estimate the adjusted models.  
Another strength of this study is that it looks at IUD insertion and removal within an 
inpatient population which is not where the majority of IUD research is focused. In conjunction 
with other IUD research, this study allows for a more holistic view of IUD usage. Although the 
use of an inpatient study sample addresses the gap in the available published data, it also represents 
one of the limitations of this study.  Since the majority of IUD insertions and removals occur in 
the outpatient setting, the obtained results may not be generalizable to the entire population of 
women with IUD-related procedures.  
Another limitation is that the data are cross-sectional and uses billing code data. The goal 
is to try to predict reasons for IUD removal, which is not possible with cross-sectional data. The 
results of this study can help encourage further prospective studies that will incorporate the 
outpatient population of IUD users and will look at IUD use longitudinally. We are bound by the 
data that was collected at the time. Because of this, we are missing some information about the 
IUD that would have been useful such as if they are using a hormonal or copper IUD and how long 
the women had the IUD inserted. Knowledge about whether the IUD was hormonal or copper may 
allow for a better prediction of allergic conditions as previous studies have shown an association 
between copper IUD use and metal-related allergic reactions23. We are also bound by the way of 
recording in the dataset which is ICD-9 codes. This may not be the best way to collect data such 
as IUD status or pre-existing chronic diseases. This is especially true within the no IUD procedure 
group as some of the women may have an IUD but there is no code for a pre-inserted IUD upon 
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admittance. NIS/AHRQ based data also does not have information about severity, laboratory 
results such as blood tests, or satisfaction with the IUD and there may be residual confounding in 
our study. 
 FUTURE DIRECTIONS 
A potential future study would be a cohort that could recruit women of reproductive age and track 
their contraceptive choices overtime along with the setting of any changes (i.e. removal or insertion 
of an IUD in a hospital versus in a doctor’s office). This would help show the different adverse 
events of different forms of contraception, how the prevalence of different forms of contraception 
change over time, and patterns that form as women change from one form of contraception to 
another. However, a cohort has the problem of selection bias in who decides to join and remain in 
the cohort. This type of study would also be much more expensive and time intensive than this 
study.  
An alternative future study could be a cross-sectional study that may be better suited to 
answering the research question than this study would be to partner with hospitals and doctor’s 
offices so that any patient who has an IUD removed with one of the partners would be asked to 
answer some questions about their health. This study would allow us to collect the exact data that 
we want while also being able to compare inpatient to outpatient IUD removals. 
Despite the limitations, the current study contributed to the IUD-related 
pharmacoepidemiologic and pharmacogenetic research conducted at the Food and Drug Agency. 
This initial research on comorbidities associated with IUD use within the inpatient population 
should be expanded for better understanding on how confounders impact IUD use, how IUD use 
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differs in the inpatient and outpatient settings, and, most importantly, what are the adverse 
outcomes exacerbated by use of an IUD and how to prevent them.  
With many options for contraception, women want to choose the best option for them. The 
high effectiveness of IUDs and few known contraindications make them the ideal choice for many 
women. A thorough understanding of the adverse events women experience and the 
subpopulations most susceptible to them is crucial in educating women on the best contraceptive 
method for them. In educating women if they are at high risk for adverse events with IUDs, 
common misconceptions about IUDs can be displaced so that women can make the most informed 
choice about their contraception. 
 PUBLIC HEALTH SIGNIFICANCE 
As healthcare providers continue to recommend IUDs to their patients, the prevalence of IUD use 
in the United States will continue to increase. With more women using IUDs, the prevalence of 
IUD related adverse events will also rise. In order to make these adverse events as preventable as 
possible, we need to gather comprehensive and actionable evidence on IUD use, which will help 
give a more holistic view of IUD benefits and potential adverse events in different women 
subpopulations. As more becomes known about IUDs, misconceptions about some exaggerated 
dangers of IUD use can be dispelled, aiding women and gynecologists in their individualized 
decisions about the best available contraception choices. 
. 
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APPENDIX: RACE-STRATIFIED DISTRIBUTION OF BASELINE 
CHARACTERISTICS 
Tables 16-18 show the distribution of baseline characteristics by race. Overall, the trends are 
very similar to those of the matched sample. 
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Table 16. Distribution of baseline characteristics among Whites. 
  
No IUD 
Procedure 
n(%) 
(N=157) 
Insertion 
n(%) 
(n=203) 
Removal 
n(%) 
(n=154) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal 
vs 
Insertion 
p-value  
Age <21 Years 11(7) 38(19) 11(7) 1.0 0.002 ̽  ̽ <0.001 ̽  ̽ 
21-
30Yyears 
68(43) 95(47) 65(49)  
  
 
31-40 Years 47(30) 49(24) 48(31)  
  
 
41-50 Years 28(18) 18(9) 27(18)  
  
 
>50 Years 3(2) 3(1) 3(2)  
  
    
  
  
Age Mean (SD) 32.4(9.5) 28.0(8.1) 32.5(9.0) 0.92 <0.001 ̽  ̽ <0.001 ̽  ̽    
  
  
Year of 
Admission 
2010 6(4) 26(13) 6(4) 1.0 0.004 ̽  ̽ 0.003 ̽  ̽
 
2011 28(18) 46(23) 6(17)  
  
 
2012 37(24) 41(20) 39(25)  
  
 
2013 48(31) 37(18) 47(31)  
  
 
2014 38(24) 53(26) 36(23)  
  
    
  
  
Length of stay Mean (SD) 2.8(3.0) 3.2(4.5) 2.9(5.0) 0.89 0.38 0.55     
  
  
Child Delivery 
Codes 
Yes 39(25) 151(74) 38(25) 0.97 <0.001 ̽  ̽ <0.001 ̽  ̽
    
  
  
Quarter of 
Discharge 
January-
March 
35(22) 35(17) 35(22) 1.0 0.10 0.10 
 
April-June 44(28) 48(24) 42(27)  
  
 
July-
September 
37(24) 42(21) 37(24)  
  
 
October-
December 
41(26) 78(38) 40(26)  
  
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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Table 17. Distribution of baseline characteristics among Blacks. 
  
No IUD 
Procedure 
n (%) 
(N=82) 
Insertion 
n (%) 
(n=86) 
Removal 
n (%) 
(n=80) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion 
vs No 
IUD Proc 
p-value  
Removal 
vs 
Insertion 
p-value  
Age <21 Years 7(9) 14(6) 6(8) 1.0 <0.001** <0.001**  
21-30 Years 21(26) 49(57) 21(26)  
  
 
31-40 Years 36(44) 14(16) 35(44)  
  
 
41-50 Years 18(22) 8(9) 18(23)  
  
 
>50 Years 0 1(1) 0  
  
    
  
  
Age Mean (SD) 34.1(8.8) 28.2(8.0) 33.3(8.8) 0.58 <0.001** <0.001**     
  
  
Year of 
Admission 
2010 4(5) 25(29) 4(5) 1.0 <0.001** <0.001** 
 
2011 12(15) 16(19) 12(15)  
  
 
2012 16(20) 18(2) 15(19)  
  
 
2013 26(32) 14(16) 26(33)  
  
 
2014 24(30) 13(15) 23(29)  
  
    
  
  
Length of Stay Mean (SD) 3.2(3.0) 3.1(3.9) 3.0(2.6) 0.70 0.82 0.93     
  
  
Child Delivery 
Codes 
Yes 14(17) 70(21) 14(18) 0.94 <0.001** <0.001** 
    
  
  
Quarter of 
Discharge 
January-
March 
1(21) 10(11) 17(21) 1.0 0.42 0.4 
 
April-June 18(22) 20(23) 18(23)  
  
 
July-
September 
19(23) 20(23) 17(21)  
  
 
October-
December 
28(34) 36(42) 28(35)  
  
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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Table 18. Distribution of baseline characteristics among other races. 
   
No IUD 
Procedur
e n (%) 
(N=178) 
Insertion 
n (%) 
(N=128) 
Removal 
n (%) 
(N=183) 
Removal 
vs No 
IUD Proc 
p-value 
Insertion vs 
No IUD Proc 
p-value  
Removal 
vs 
Insertion 
p-value  
Age <21 Years 10(6) 18(14) 10(6) 1.0 <0.001** <0.001**  
21-30 Years 60(34) 60(47) 59(32)  
  
 
31-40 Years 67(38) 38(30) 70(38)  
  
 
41-50 Years 40(22) 7(5) 43(24)  
  
 
>50 Years 1(0.5) 5(4) 1(0.5)  
  
    
  
  
Age Mean (SD) 33.5(8.5) 29.6(8.6) 33.9(8.2) 0.66 <0.001** <0.001 **     
  
  
Year of 
Admission 
2010 7(4) 31(24) 7(4) 1.0 <0.001** <0.001** 
 
2011 53(30) 21(16) 53(29)  
  
 
2012 39(22) 22(17) 39(21)  
  
 
2013 39(22) 25(20) 42(23)  
  
 
2014 40(22) 29(23) 42(23)  
  
    
  
  
Length of 
Stay 
Mean (SD) 3.0(3.6) 2.7(1.3) 3.9(8.0) 0.16 0.34 0.08 
    
  
  
Child 
Delivery 
Codes 
Yes 60(34) 107(84) 58(32) 0.68 <0.001** <0.001** 
    
  
  
Quarter of 
Discharge 
January-
March 
40(22) 24(19) 42(23) 0.98 0.40 0.27 
 
April-June 32(18) 28(22) 34(19)  
  
 
July-
September 
47(26) 26(20) 50(27)  
  
 
October-
December 
59(33) 50(39) 57(31)  
  
*=significance at the nominal 0.05 level **= significance at the 0.01 level to account for multiple testing. 
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